Tesamorelin vs DSIP
A comprehensive, data-driven comparison of Tesamorelin (Egrifta) and DSIP (Delta Sleep-Inducing Peptide). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Tesamorelin Egrifta, TH9507 | DSIP Delta Sleep-Inducing Peptide |
|---|---|---|
| FDA Status | FDA Approved | Category 2 |
| Category | Growth Hormone | Sleep |
| Primary Use | HIV-associated lipodystrophy | Sleep disorders and stress reduction |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $200 - $1,500/mo | $35 - $70/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 2mg daily | 100-300mcg before bed |
| Frequency | Daily | Daily |
| Mechanism | Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production | Neuropeptide that may modulate sleep patterns, reduce stress, and regulate circadian rhythms |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Emerging |
| Clinical Trial Phase | Approved | N/A |
Key Differences
- 1Tesamorelin is FDA-approved, while DSIP is currently category 2.
- 2DSIP is generally more affordable ($35 - $70/mo) compared to Tesamorelin ($200 - $1,500/mo).
- 3Tesamorelin has high-quality evidence, while DSIP has emerging-quality evidence.
- 4They belong to different categories: Tesamorelin (Growth Hormone) vs DSIP (Sleep).
Which Is Better For...
Tesamorelin
Those seeking an FDA-approved treatment with established safety data
DSIP
More budget-friendly option with lower monthly costs
DSIP
Fewer commonly reported side effects
Tesamorelin
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Tesamorelin | $200 - $1,500/mo | FDA Approved | Theratechnologies |
| DSIP | $35 - $70/mo | Category 2 | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Tesamorelin works via Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone. DSIP works via Neuropeptide that may modulate sleep patterns, reduce stress, and regulate circadian rhythms. They differ in FDA approval status, efficacy data, and cost.
Tesamorelin typically costs $200 - $1,500/mo, while DSIP costs $35 - $70/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Tesamorelin is FDA-approved. DSIP is not FDA-approved (Category 2). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Tesamorelin include Injection site reactions, Arthralgia, Peripheral edema. Common side effects of DSIP include Injection site reactions, Drowsiness, Vivid dreams. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Tesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A new weekly reco...
View Full Tesamorelin GuideDSIP (Delta Sleep-Inducing Peptide) is a neuropeptide first discovered in 1977 in the brains of sleeping rabbits. Research suggests it may have broader effects on stress response, pain modulation, and...
View Full DSIP GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Tesamorelin and DSIP should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.